Floxuridine
Floxuridine (floxuridine) is a small molecule pharmaceutical. Floxuridine was first approved as Fudr on 1982-01-01. It is used to treat colorectal neoplasms and stomach neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Floxuridine (discontinued: Floxuridine, Fudr)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| floxuridine | ANDA | 2024-10-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| colorectal neoplasms | — | D015179 | — |
| stomach neoplasms | EFO_0003897 | D013274 | C16 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9200 | Injection, floxuridine, 500 mg |
Clinical
Clinical Trials
71 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 2 | — | 1 | — | 3 |
| Pancreatic ductal carcinoma | D021441 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 4 | 21 | 11 | — | 1 | 35 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 8 | 10 | 8 | — | 2 | 26 |
| Neoplasms | D009369 | — | C80 | 6 | 10 | 5 | — | 2 | 22 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 6 | 1 | — | 1 | 10 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 8 | 1 | — | — | 9 |
| Colonic neoplasms | D003110 | — | C18 | 2 | 4 | 1 | — | 1 | 7 |
| Carcinoma | D002277 | — | C80.0 | 3 | 3 | 1 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | D018281 | — | C22.1 | 3 | 8 | — | — | 2 | 12 |
| Rectal neoplasms | D012004 | — | — | 2 | 4 | — | — | — | 5 |
| Adenocarcinoma | D000230 | — | — | — | 5 | — | — | — | 5 |
| Esophageal neoplasms | D004938 | — | C15 | — | 3 | — | — | — | 3 |
| Recurrence | D012008 | — | — | 1 | 3 | — | — | — | 3 |
| Bile duct neoplasms | D001650 | — | — | — | 1 | — | — | 1 | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | — | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Floxuridine |
| INN | floxuridine |
| Description | Floxuridine is a pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. It has a role as an antineoplastic agent, an antimetabolite, an antiviral drug and a radiosensitizing agent. It is a pyrimidine 2'-deoxyribonucleoside, an organofluorine compound and a nucleoside analogue. |
| Classification | Small molecule |
| Drug class | antivirals; antineoplastics (uridine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F |
Identifiers
| PDB | — |
| CAS-ID | 50-91-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL917 |
| ChEBI ID | 60761 |
| PubChem CID | 5790 |
| DrugBank | DB00322 |
| UNII ID | 039LU44I5M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,290 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
80 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use